Eli Lilly
Lilly’s Tirzepatide Demonstrates Significant Reduction in Diabetes Risk and Sustained Weight Loss in Overweight Adults
tirzepatide, diabetes risk reduction, sustained weight loss, overweight adults, pre-diabetes, obesity, Eli Lilly, Mounjaro, Zepbound
Eli Lilly Unveils State-of-the-Art Genetic Medicine Research Center in Boston
Eli Lilly, Boston, genetic medicines, research center, innovation hub, biotech
Lilly Opens State-of-the-Art Research and Development Center in Boston
Lilly, Boston, research and development, genetics research, biotech incubator, East Coast hub
Lilly’s Blockbuster GLP-1 Drugs Removed from FDA Shortage List
Lilly, GLP-1, FDA, drug shortage, Mounjaro, Zepbound, tirzepatide
Eli Lilly’s Mounjaro and Zepbound Return to Stock After Extended Shortage, FDA Announces
Eli Lilly, Mounjaro, Zepbound, FDA, drug shortage, weight loss medication, diabetes medication
Lilly’s Tirzepatide Clears Phase III Cardiovascular Study on Heels of Novo Nordisk’s Semaglutide
Tirzepatide, Lilly, Phase III, Cardiovascular Study, Novo Nordisk, Semaglutide, Heart Failure, Obesity, Weight Loss
Sun Pharma Secures FDA Approval for Leqselvi, a JAK Inhibitor for Severe Alopecia Areata
Sun Pharma, Leqselvi, FDA Approval, Alopecia Areata, JAK Inhibitor, Pfizer, Lilly, Immunology, Dermatology
Layoffs Persist, GLP-1s Launch for Weight Loss in China
GLP-1, weight loss, China, Novo Nordisk, Eli Lilly, layoffs, biopharma industry, semaglutide, tirzepatide, obesity, diabetes
Eli Lilly, Novo Nordisk Shares Fall as their weight-Loss drugs face competition
, Eli Lilly, Novo Nordisk, Roche, Obesity drugs, Weight-loss drug market, Stock market, Pharmaceutical competition, GLP-1 therapy, CT-996, Zepbound, Wegovy,
Innovent Achieves Another Phase 3 Victory in China for Next-Generation Lilly GLP-1 Drug
Innovent Biologics, Lilly, GLP-1, Mazdutide, Phase 3 Trial, Type 2 Diabetes, Weight Loss, China